A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With HR+ / HER2- Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in Spain
Latest Information Update: 17 Jan 2025
Price :
$35 *
At a glance
- Drugs Capivasertib (Primary) ; Fulvestrant
- Indications HER2 negative breast cancer; HER2 positive breast cancer; Male breast cancer
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 13 Jan 2025 Planned End Date changed from 31 Dec 2027 to 31 Jan 2028.
- 13 Jan 2025 Planned primary completion date changed from 31 Dec 2027 to 31 Jan 2028.
- 13 Jan 2025 Status changed from not yet recruiting to recruiting.